Literature DB >> 17873133

Limitations of CT during PET/CT.

Marc J Gollub1, Richard Hong, Debra M Sarasohn, Tim Akhurst.   

Abstract

UNLABELLED: Our aim was to determine the diagnostic limitations of low-dose, unenhanced CT scans performed for anatomic reference and attenuation correction during PET/CT.
METHODS: The Radiology Information System at our oncologic hospital was queried during the 9-mo period from July 2002 to April 2003 for patients with PET/CT scans and diagnostic enhanced CT within 2 wk of each other. One radiologist interpreted the CT portion of the PET/CT (CT(p)) unaware of the PET results and the associated enhanced diagnostic CT (CT(d)). A medical student compared this interpretation with the official report of the CT(d) and listed all discrepancies between reports. A separate radiologist compared CT(p) and CT(d) images and classified true discrepant findings as due to lack of intravenous contrast, arm-position artifact, lack of enteric contrast, low milliamperage (mA), and quality of lung images.
RESULTS: Among 100 patients, the most common malignancies were lymphoma (n = 37), cancer of the colorectum (n = 31), and esophageal cancer (n = 15). Among 194 true discrepancies in which findings were missed at CT(p), causes were as follows: (a) lack of intravenous contrast (128/194, 66%), (b) arm-down artifact (17/194, 9%), (c) quality of lung images (26/194, 13%), (d) lack of enteric contrast (15/194, 8%), and (e) low mA (8/194, 4%). Discrepancies were seen most commonly in detecting lymphadenopathy and visceral metastases.
CONCLUSION: Most missed findings on the unenhanced CT portion of the PET/CT scans were due to technical factors that could be altered. Discrepant findings would have led to altered management in only 2 patients, suggesting a role for limited repeat imaging to reduce radiation and use of valuable resources.

Entities:  

Mesh:

Year:  2007        PMID: 17873133     DOI: 10.2967/jnumed.107.043109

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

1.  Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT.

Authors:  Shu-Hang Ng; Sheng-Chieh Chan; Tzu-Chen Yen; Chun-Ta Liao; Joseph Tung-Chieh Chang; Sheung-Fat Ko; Hung-Ming Wang; Chin-Yu Lin; Kai-Ping Chang; Yu-Chun Lin
Journal:  Eur Radiol       Date:  2010-09       Impact factor: 5.315

2.  FDG-PET scans in patients with lymphoma.

Authors:  Rebecca L Elstrom; John P Leonard
Journal:  Curr Hematol Malig Rep       Date:  2008-10       Impact factor: 3.952

3.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

Authors:  Sally F Barrington; N George Mikhaeel; Lale Kostakoglu; Michel Meignan; Martin Hutchings; Stefan P Müeller; Lawrence H Schwartz; Emanuele Zucca; Richard I Fisher; Judith Trotman; Otto S Hoekstra; Rodney J Hicks; Michael J O'Doherty; Roland Hustinx; Alberto Biggi; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

4.  PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.

Authors:  Thomas Pfluger; Henriette Ingrid Melzer; Vera Schneider; Christian La Fougere; Eva Coppenrath; Carola Berking; Peter Bartenstein; Mayo Weiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

5.  Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up.

Authors:  Shu-Hang Ng; Sheng-Chieh Chan; Tzu-Chen Yen; Joseph Tung-Chieh Chang; Chun-Ta Liao; Sheung-Fat Ko; Feng-Yuan Liu; Shu-Chyn Chin; Kang-Hsing Fan; Cheng-Lung Hsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-15       Impact factor: 9.236

Review 6.  Current role of FDG PET/CT in lymphoma.

Authors:  Lale Kostakoglu; Bruce D Cheson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-12       Impact factor: 9.236

7.  Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT.

Authors:  Shu-Hang Ng; Sheng-Chieh Chan; Tzu-Chen Yen; Joseph Tung-Chieh Chang; Chun-Ta Liao; Sheung-Fat Ko; Hung-Ming Wang; Yau-Yau Wai; Jiun-Jie Wang; Min-Chi Chen
Journal:  Eur Radiol       Date:  2009-12       Impact factor: 5.315

8.  Incremental value of integrated FDG-PET/CT in evaluating indeterminate solitary pulmonary nodule for malignancy.

Authors:  Chih-Yung Chang; Ching Tzao; Shih-Chun Lee; Cheng-Yi Cheng; Chang-Hsien Liu; Wen-Sheng Huang; Chih-Hung Ku; Jong-Kang Lee; Ching-Yee Oliver Wong
Journal:  Mol Imaging Biol       Date:  2009-06-20       Impact factor: 3.488

9.  Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma.

Authors:  R L Elstrom; J P Leonard; M Coleman; R K J Brown
Journal:  Ann Oncol       Date:  2008-06-10       Impact factor: 32.976

10.  PET/CT: Current status in India.

Authors:  Venkatesh Rangarajan; Nilendu C Purandare; Anshu R Sharma; Sneha Shah
Journal:  Indian J Radiol Imaging       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.